Houston health tech startups announce exec, funding — plus more innovation news

SHORT STORIES

Houston's health tech and startup ecosystem has some recent news to catch up on. Photo via Getty Images

Houston startup founders have been moving and shaking in the local innovation ecosystem — from growing their executive boards to raising fresh grant funding.

In this roundup of Houston startup and innovation news, a startup opens a crowdfunding round, a Houston hospital system taps into new technology, and more.

Coya Therapeutics names new president and chief medical officer

Fred Grossman will assume his new role next week. Photo via LinkedIn

Coya Therapeutics Inc. (NASDAQ: COYA), a revolutionary biotech company based in Houston, named Dr. Fred Grossman as president and chief medical officer. The clinical-stage company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

According to the company, Dr. Grossman's position, which was held by Dr. Adrian Hepner, is effective July 17.

“We are grateful for Dr. Hepner’s leadership and excellence in positioning Coya and look forward to having him continue to collaborate with the company in moving our assets forward," Howard H. Berman, CEO of Coya, says in a news release. "We also welcome Dr. Grossman, who brings decades of clinical development experience and successful execution."

Dr. Grossman has held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Sunovion, Glenmark Pharmaceuticals, and Mesoblast Inc. (NASDAQ: MESO), developing allogeneic cellular therapies for inflammatory diseases.

CellChorus receives another SBIR grant

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured additional funding. Photo via Getty Images

Fresh off a $2.3 million grant last month, Houston-based CellChorus, a single-cell analysis company, has another grant to celebrate.

The U.S. National Science Foundation has awarded CellChorus a Small Business Innovation Research (SBIR) grant to advance development of its Time-lapse Imaging Microscopy In Nanowell Grids, known as TIMING. The funding will be used to develop novel microscale arrays to support scaling dynamic single-cell analysis.

“This funding will further development of novel arrays to build on the success of our early access laboratory based in Houston,” says Mohsen Fathi, head of technology at CellChorus, in a press release. “This project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies.”

According to the release, the company is receiving more than $274,000 as a part of the grant, but CellChorus has the potential of receiving up to $2 million from the second phase.

“This award builds on our recent funding from the National Institute of General Medical Sciences to advance development of a dedicated instrument platform for TIMING,” says Daniel Meyer, CEO of CellChorus, in the release.

Memorial Hermann partners with TMC-backed virtual OB-GYN care

Two Houston-area hospitals now have access to this digital health startup's platform. Photo via Getty Images

The Memorial Hermann Health System has entered into a partnership with Washington, D.C.-based Babyscripts, a virtual care platform for managing obstetrics. The company is backed by the Texas Medical Center's venture fund and has existing ties to the city.

"Memorial Hermann strives to make Greater Houston a place where every woman's pregnancy, delivery and postpartum experience is successful and safe. This innovative partnership is a continuation of that commitment," says Dr. Victoria Regan, vice president of Women's and Children's Services at Memorial Hermann, in a news release.

Now, Memorial Hermann patients will be able to access Babyscripts myJourney, an app that delivers educational content, email campaigns, satisfaction surveys, appointment reminders, and more. The first two hospitals to receive access are Memorial Hermann Memorial City Medical Center and Memorial Hermann The Woodlands Medical Center, with plans to expand the program.

"The ability to access adequate prenatal and postpartum care is one of the largest predictors of maternal and infant health outcomes," says Anish Sebastian, CEO and co-founder of Babyscripts in the release. "With Babyscripts, Memorial Hermann is able to streamline the maternal health experience across their system, adding opportunities for access and providing consistent, high-quality pregnancy care to all patients, regardless of race, income, geography or risk."

Earn Your Freedom launches crowdfunding campaign with Houston nonprofit's support

Earn Your Freedom is looking for financial support from its community. Photo via houston.impacthub.net

Earn Your Freedom, a Houston startup that's gamifying personal finance education, has launched its first crowdfunding campaign in partnership with Impact Hub Houston.

The goal for EYF is to raise $100,000 to support its gaming programs with local schools. Impact Hub Houston is the fiscal sponsor for the raise, which is officially live and open for contributions.

The innovative and interactive web and mobile video game, which officially launched earlier this year to celebrate Financial Literacy Month, was designed to help kids build a strong foundation in money management, economics and investment in a fun and engaging way. It features challenges and real-world scenarios such as renting a first apartment, opening a first bank account, budgeting at the grocery store, buying stocks and index funds and renting or buying real estate.

“We envision a society where financial literacy is accessible to all, and where individuals are enabled with the tools to take control of their financial futures," says Keely McEnery, EYF co-founder and COO, in a press release. "We are bridging the gap between education and application, stepping in before the real-world consequences take place.”

From Your Site Articles
Coya Therapeutics rang the closing bell at Nasdaq last week, celebrating six months since its IPO, new data from trials, and additions to its team. Photo via LinkedIn

Houston company with revolutionary neurodegenerative disease treatment shares milestones since IPO

ring that bell

After announcing its initial public offering earlier this year, a Houston therapeutics company has celebrated the milestone and announced recent growth as well.

Coya Therapeutics (Nasdaq: COYA) rang the closing bell last week. The clinical-stage biotech company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

"We launched our IPO into one of the toughest biotech capital markets in recent memory and are enormously grateful to all our investors for the confidence they then showed in our prospects," says Howard Berman, CEO and chairman of Coya, in a June 12 letter to stockholders. "I believe that to date, we’ve executed strongly against the goals we then established, and I remain excited about our future."

In the letter, Berman shares some of the recent clinical successes from two treatments — COYA 302, a treatment for ALS, and COYA 301, a treatment for Alzheimer’s Disease. Both treatments have seen strong clinical proof of concept data in the respective open-label studies.

Earlier this year, Coya expanded its C-suite to include Dr. Arun Swaminathan as chief business officer. He has over 20 years of hands-on health care business executive experience. Prior to Coya, Swaminathan served in the same role for Actinium Pharmaceuticals.

"Arun is actively engaged in exploring potential strategic opportunities across our portfolio of assets as we believe successful partnering efforts have the potential to enhance our scientific bona fides, leverage our technology into new areas of unmet medical need, and importantly, possibly secure upfront fees and associated non-dilutive funding," Berman writes in the letter. "We look forward to pursuing additional value creation catalysts that further highlight our entrepreneurialism and ability to execute, while maintaining focus on our core assets."

The latest addition to the Coya team is Guillaume Dorothée, who joins the company's scientific advisory board. A leading expert on the role that the immune system and peripheral-central immune crosstalk play in the pathophysiology of Alzheimer's, he's a tenured research director and team head in neuroimmunology at the French National Institute of Health and Medical Research in Paris.

“I am glad and honored to join such eminent scientists on the prestigious SAB of Coya Therapeutics," he says in a June 5 statement from Coya. "I am fully convinced that innovative Treg-based immunomodulatory approaches, as developed by Coya, are highly promising therapeutic strategies for the treatment of neurodegenerative disorders and other neuroinflammatory conditions. I will be happy to help Coya Therapeutics in this exciting endeavor.”

Recently, Berman joined the Houston Innovators Podcast to discuss Coya's mission and plan post IPO.


This week's roundup of Houston innovators includes Howard Berman of Coya Therapeutics, Tim Latimer of Fervo Energy, and Jim Sledzik of Aramco Ventures. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from biotech to energy transition — recently making headlines in Houston innovation.

Howard Berman, co-founder and CEO of Coya Therapeutics

For Howard Berman, CEO and co-founder of Coya Therapeutics, commercializing his company is personal. Photo courtesy of Coya

Howard Berman, as co-founder and CEO, has been at the helm of Coya Therapeutics as its hit some major milestones — from raising over $20 million in venture investment to taking the company public. Coya's IPO occured in a tough market — only 12 biotech companies went public last year, Berman explains on the Houston Innovators Podcast. To Berman, that just proves how passionate the team was about getting this product to those who need it.

"It really says something for the fortitude and our team to come together to make it happen," he says on the show. "We're able to deliver and execute in a difficult market climate.

"Once you're a public company, you have different expectations," he continues. "But you also have the opportunity to go out and attract additional investors in ways you can't do as a private company." Read more.

Tim Latimer, co-founder and CEO of Fervo Energy 

Fervo Energy has raised additional funding to continue executing on its mission of more reliable geothermal energy production. Photo via LinkedIn

Fervo Energy, which has developed a process for drilling horizontal wells for commercial geothermal production as well as distributed fiber optic sensing to geothermal reservoir development, has secured the $10 million strategic investment from Devon Energy Corp.

“We are thrilled to have Devon as a partner,” says Tim Latimer, co-founder and CEO of Fervo, in a news release. “Devon is a technology leader with historic and unparalleled expertise in drilling and completing wells. We expect this partnership will help unlock further potential for geothermal as the primary 24/7 renewable energy source.” Read more.

Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures

Jim Sledzik, North American managing director of Saudi Aramco Energy Ventures, will serve on Greentown's Industry Leadership Council. Photo via Aramco

Houston-based Aramco Americas, an arm of the Saudi Arabian energy giant, has joined climatetech incubator Greentown Labs as a top-tier partner.

In its role as a “Terawatt Partner,” Aramco Americas will gain access to activities within Greentown’s industry and entrepreneurial network. In addition, Aramco Americas will participate in Greentown’s Industry Leadership Council, an advisory group. Jim Sledzik, managing director of Aramco Ventures North America, will serve on the council. Read more.

For Howard Berman, CEO and co-founder of Coya Therapeutics, commercializing his company is personal. Photo courtesy of Coya

Why this Houston innovator is racing to commercialize its unique treatment for neurodegenerative diseases

HOUSTON INNOVATORS PODCAST EPISODE 182

When Howard Berman sought out renowned Houston Methodist researcher and neurologist Dr. Stanley Appel, he was looking for treatment for his father, who was suffering from dementia. He wasn't looking for a job, but Dr. Appel had other ideas and asked Berman to meet with him.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Not too long after that meeting, Berman, who founded digital health platform imaware, joined Dr. Appel to lead commercialization of Coya Therapeutics, a biotech startup that raised over $20 million in venture funding before going public a few months ago.

Coya has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again. Diseases like ALS, the company's focus right now, prevent T-regs from doing their job in controlling inflammation, and without these cells hard at work, the human body doesn't stand a chance in fighting autoimmune threats.

Berman, as co-founder and CEO, has been at the helm of the company leading it through both the fundraising and IPO processes. Coya's IPO occured in a tough market — only 12 biotech companies went public last year, he explains. To Berman, that just proves how passionate the team was about getting this product to those who need it.

"It really says something for the fortitude and our team to come together to make it happen," he says on the show. "We're able to deliver and execute in a difficult market climate.

"Once you're a public company, you have different expectations," he continues. "But you also have the opportunity to go out and attract additional investors in ways you can't do as a private company."

For Berman, whose father passed away earlier this year, it's a personal motivation that drives him to lead the company — as well as an opportunity to advance the city of Houston.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


This week's roundup of Houston innovators includes Steve Latham of DonateStock, Arianne Dowdell of Houston Methodist, and Howard Berman of Coya Therapeutics. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from fintech to health care DEI — recently making headlines in Houston innovation.

Steve Latham, co-founder and CEO of DonateStock

Houstonian and serial entrepreneur plans to scale nonprofit fintech toolThe sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

For the third time in his career, serial entrepreneur Steve Latham recession activity, so he feels confident he knows the playbook of how to handle what's on the horizon. For his latest venture, Donate Stock, a tech platform that simplifies stock donation for both the donor and the beneficiary, he's focused on weathering whatever storm is incoming.

"We've raised more money to extend our runway, and we're keeping a super tight lid on expenses because your cash is your oxygen," he says. "There are companies going out of business in our industry right now that had really promising businesses but just spent too much money before they could get to the revenue phase."

He shares the background story on DonateStock and his own career on last week's Houston Innovators Podcast episode. Read more and stream the episode.

Arianne Dowdell, vice president and chief diversity, equity and inclusion officer at Houston Methodist

Arianne Dowdell spoke with InnovationMap about Houston Methodist's DEI initiatives — and how they will help develop the hospital of the future. Photo courtesy of Houston Methodist

Innovation and equity are two things they have to go together — and Houston Methodist knows that. Which is why Arianne Dowdell serves as vice president and chief diversity, equity and inclusion officer at Houston Methodist. Under her leadership, the health care provider is putting the patients at the forefront of the hospital system's priorities through its DEI initiatives.

In an interview with InnovationMap, Dowdell shares more about these ongoing initiatives and her role, as well as the importance of DEI in innovative health care.

"It doesn't matter if you're down here in the medical center or out in Baytown," she says. "The innovation and what we're thinking about and the technologies and the way that we communicate with our patients, all that is part of innovation, which helps our DEI initiatives become more successful in everything that we're doing." Read more.

Howard Berman, CEO of Coya Therapeutics

A Houston biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has closed its IPO. Photo courtesy of Coya

A clinical-stage biotech company based in Houston has announced the closing of its $15.25 million IPO.

Coya Therapeutics, now trading under the ticker COYA, announced this week that its IPO — previously disclosed in December — has closed its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock, per a news release. Howard Berman, CEO of Coya Therapeutics, has lead the company since February of 2021. Read more.

A biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has some big news to share. Photo via Getty Images

Houston biotech startup announces merger and $10M series A

getting ahead

A Houston company has emerged from stealth mode to announce a merger and a round of financing.

Coya Therapeutics, a clinical-stage biotech startup that focuses on creating therapeutics for neurodegenerative and autoimmune diseases, announced that it has completed a merger with Nicoya Health Inc. and raised $10 million in its series A. The round was led by Florida-based Allele Capital Partners LLC. Howard Berman, founder and board of directors for imaware, has been named CEO of Coya, as well as a member of the company's board of directors.

Coya's therapeutics uses innovative work from Dr. Stanley H. Appel, co-director of Houston Methodist Neurological Institute and Chair of the Stanley H. Appel Department of Neurology at Houston Methodist Hospital. The researcher has created a way to "isolate dysfunctional Tregs from a patient, convert them to a highly functional and neuroprotective condition, and expand these cells into the billions for intravenous reinfusion back to the patient," says Berman in a news release. This revolutionary work overcomes previous limitations in the field.

"I'm excited to have the opportunity to lead Coya at such an exciting and pivotal phase of growth," Berman says. "Through our sponsored research program in conjunction with Dr. Appel, we look forward to continuing advancement of this promising work and translating this work into a meaningful therapy for patients."

The company's fresh funds will be used to continue work on the company's lead therapeutic program, ALS001, an autologous, expanded Treg cell therapy for amyotrophic lateral sclerosis (ALS) patients , as well as to introduce clinical pipeline candidates targeting Parkinson's disease, Alzheimer's disease, frontal temporal dementia, and more, according to the release.

"Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great potential in unlocking a new treatment paradigm and may enable us to revolutionize care for patients with devastating neurodegenerative diseases," says Appel. "We have successfully demonstrated, in a phase 1 trial, the safety and tolerability of autologous infusions of expanded Tregs in ALS patients, with the potential of slowing or halting disease progression. Ongoing studies provide a transformative framework for advanced clinical trials in ALS and other neurodegenerative disorders."

Tribal Capital Markets LLC acted as sole placement agent for the offering, according to the release, and Allele Capital Partners — through Tribal Capital Markets — was responsible for sourcing, investing and executing the $10 million offering.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Real estate giant taps downtown Houston tower for new smart building tech

hi, tech

Houston-based real estate giant Hines is rolling out a new smart building platform with the goal of better serving workers and workplaces at its buildings across the country, including one building in Houston that's aiming to be an office building of the future.

From the employee perspective, the new Hines app will allow employees and employers to book spaces within buildings, order food from on-site cafes and restaurants, book on-site fitness classes and access the building via their smartphone or smartwatch. For employers and tenants, the app will help them gain insights into building performance, occupancy data, ESG targets and employee satisfaction, according to a statement from Hines.

“We’re committed to a people-centric experience and this investment takes that commitment to the next level,” Ilene Goldfine, chief digital strategy officer at Hines, says in a statement. “The traditional systems were managed building by building and made it difficult or impossible to track performance across a portfolio. This new digital ecosystem, which unites back-end technology with front-end experiences, will deliver long-term cost savings to our investors and clients.

"Our clients will also be able to track employee satisfaction, make informed decisions about their space needs and ensure they’re monitoring their carbon targets,” Goldfine continues.

The new digital platform will be launched at eight Hines buildings across five cities, including 717 Texas Ave., a 33-story Class A office tower in Downtown Houston.

The other buildings where Hines will roll out the app include:

  • Salesforce Tower in Chicago
  • 1144 15th Street in Denver
  • The Kearns Building in Salt Lake City
  • CIBC Square in Toronto
  • T3 Bayside in Toronto
  • Two buildings at T3 Sterling Road in Toronto

The company plans to add more locations across its global portfolio.

Hines' opened its first location of The Square coworking space at 717 Texas Ave. in 2020 as part of its coworking concept Hines². The company, in collaboration with Montreal-based Ivanhoé Cambridge, opened a second Houston location of The Square recently and has a coworking space in The Kearns Building in Salt Lake City where it will roll out the new app.

Earlier this year, Hines also launched a sustainability-focused business unit, known as EXP by Hines. The unit, led by Hines veteran Doug Holte, aims to address “the disruptive changes in the built environment.”

Houston expert encourages energy industry to bridge its generational divides

guest column

What’s the biggest obstacle between us and net-zero? Is it policy? Technology? Financing? All of these are important, yes, but none of them is what is really holding us back from our energy transition goals.

The biggest obstacle is a lack of open-mindedness and an unwillingness of people across the industry and across generations to work together.

In October of 2022, I was invited to speak at Energy Dialogues’s North American Gas Forum, a conference that brings together executives from across the energy industry. Over the two days of the conference, I was amazed by the forward-thinking conversations we were having on decarbonization, the future of clean energy, emissions reduction, and much more. I returned back to campus at Duke University, energized by these conversations and excited to share them. But rather than seeing the same sense of excitement, I was met with doubt, disbelief, even scorn.

There’s a fundamental distrust between generations in this industry, and it goes both ways. Experienced energy professionals often see the younger generation as irrational idealists who are too politicized to be pragmatic, while the younger generation often paints the older generation as uncaring climate denialists who want nothing to do with clean energy. Neither is true.

Over the past two years since founding Energy Terminal, I’ve met hundreds (maybe thousands) of people all across the energy industry, from CEOs of major energy companies to students just getting started on their career journey. Despite being so different on the surface, their goals are strikingly similar. Almost all can agree on three things: we want to reduce emissions, we want to expand energy access, and we want to do so while encouraging economic prosperity. The perceived barrier between generations in the energy industry is exponentially larger than the actual barrier.

For experienced professionals — take a chance to engage in conversations with young energy leaders. Understand their priorities, listen to their concerns, and find the middle ground. We are a generation passionate about impact and growth, and enabled with the right resources, we can do incredible things. The changing energy world presents unbelievable opportunities for both progress and profit, but without the next generation on board, it will never be sustainable.

For the young energy leaders of the future–listen to the experiences of the leaders that have come before us. Understand the balance between energy that is clean with energy that is secure, reliable, and affordable. We have brilliant ideas and an insatiable appetite for progress, but we won’t do it alone. Every person and every company has a valuable role to play in the energy transition, so consider how we can amplify our strengths rather than attack each other’s weaknesses.

If my co-founder, a climate activist from New York, and myself, the son of an oil and gas family from south Texas, can do it, so can you. This is a call to find the middle ground, to open up your mind to new possibilities, and to make real progress by working with each other rather than against each other.

------

Michael Wood III is co-founder of Energy Terminal, a platform that aims to build the next generation of energy leaders and to bridge the gap between youth and the energy industry.

This article originally ran on EnergyCapital.

Rice researchers score $45M from NIH for cancer-fighting tech

freshly funded

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

View All Listings